Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
01.08
2020
Addex to Attend 38th Annual J.P. Morgan Healthcare Conference
12.20
2019
Addex to Receive Additional $800K Funding from Indivior for GABAB PAM Addiction Program
12.18
2019
ADDEX THERAPEUTICS PUBLICLY FILES REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSs REPRESENTING SHARES
12.03
2019
Addex: Van Leeuwenhoeck Issues Update Equity Research Report
11.13
2019
Addex to Attend Jefferies 2019 London Healthcare Conference
11.08
2019
Addex to Present at 25th Annual BIO-Europe Conference in Hamburg
10.08
2019
Addex to Receive Additional Funding from Indivior for GABAB PAM Addiction Program
09.30
2019
Addex Reports 2019 Half-Year Financial Results and Provides Corporate Update
09.25
2019
ADDEX THERAPEUTICS TO RELEASE HALF-YEAR 2019 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON SEPTEMBER 30, 2019
09.24
2019
ADDEX THERAPEUTICS SUBMITS REGISTRATION STATEMENT WITH THE U.S. SEC TO FACILITATE NASDAQ LISTING OF ADSS REPRESENTING SHARES
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back